Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Helius Medical Technologies Inc HSDT

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.


NDAQ:HSDT - Post by User

Comment by CREAMSHOWon Sep 01, 2016 11:24am
87 Views
Post# 25199355

RE:RE:RE:September Announcement

RE:RE:RE:September AnnouncementYes that was from Fabrice Taylor's newsletter. Do you think he got it mixed up? I think if he had made a mistake he would of corrected himself in a update.. but you have a good point. GLTA CREAMSHOW
prokofiev wrote: I think he is referring to the original post from CREAMSHOW (who I believe is subscribed to Frabice's newsletter) LINK TO POST whish states:

"We will get an important data point in September, when preliminary results from the traumatic brain injury trial are released. We are very confident that the company will breeze through this milestone and look forward to the big news, likely in a few short months, that will determine if this technology works for TBI."

I believe Frabrice confused the trial data to be released. It is not the interim results from the Registrational Phase III trial  (the one which results will be submitted to FDA) that will be release, but the ones from the the long-term TBI study at the University of  Wisconsin – Madison  LINK.




vancity604 wrote: When is the announcement and what is the source for this information or is this just speculation? Same with your Fabric Taylor comment... is this just a guess?




Bullboard Posts